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Summary 
Acute myelogenous leukemia (AML) is an aggressive malignancy characterized by accumulation of 
immature myeloid cells in the bone marrow. The overall disease-free survival is less than 50% even 
for the younger patients who can receive the most intensive treatment and hence, there is obviously a 
need for an improved therapy.  
 
Short time until lymphoid reconstitution after chemotherapy seems to be a good prognostic factor in 
several malignancies, including AML, and targeting of autologous T cells is considered a possible 
therapeutic approach. Thus, the major aim of this thesis was to further characterize the immune 
system of patients with AML. 
 
Disease and therapy induced T lymphocyte defects may contribute to the immune defects in AML. 
We therefore characterized the T lymphocytes of untreated AML patients as well as the remaining T 
cells in AML patients receiving intensive chemotherapy. Untreated AML patients were found to have 
close to normal lymphocyte subset ratios and also the in vitro T cell activation response, release of 
IFN, was close to normal after adjustment of cell numbers. In contrast, the released levels of IFN 
and GM-CSF cytokines from in vitro activated T cells in whole blood from cytopenia AML patients 
were lower than for healthy controls. However, the IFN and GM-CSF levels could be further 
increased by the protein kinase C agonist Pep005. The direct effects of the IFN on AML blasts 
included altered i) cytokine-dependent AML cell proliferation, ii) viability, and iii) balance between 
pro- and antiangiogenic chemokine release. 
 
Several mutated or overexpressed proteins seem to be processed and presented to the immune system 
as tumor antigens leading to humoral and/or cellular responses. Autoantibodies are thus common in 
cancer patients but the autoantibody response in AML patients has been included in relatively few 
previous studies. Our studies report aberrant cyclin B1 expression in primary AML cells and 
detection of anti-cyclin B1 in a subset of sera from AML patients. In contrast, no autoantibodies 
against the typically SLE associated antigen P-protein could be detected in sera from untreated and 
chemotherapy treated AML patients. 
 
To conclude, both the cellular and humoral immune system in AML patients differ from healthy 
controls. However, our results support the hypothesis that even these immunocompromized patients 
have remaining immunocompetent cells that can be targeted by immunotherapy.  
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INTRODUCTION 
1. Acute myelogenous leukemia 
 
Acute myelogenous leukemia (AML) is a hematological malignancy characterized by clonal 
proliferation of immature myeloid precursors and an arrest in the maturation of these cells (1). This 
results in accumulation of leukemic blasts in the bone marrow (BM) and eventually in the peripheral 
blood (PB); other tissues are usually not affected. The bone marrow infiltration causes a decrease in 
the production and thereby a reduction of the peripheral blood levels of mature myeloid cells; 
platelets (resulting in thrombocytopenia and eventually hemorrhages), erythrocytes (anemia) and 
neutrophils (granulocytopenia and eventually infections). The initial presentation of patients with 
AML is with symptoms often related to this pancytopenia (i.e., thrombocytopenia, anemia, and 
neutropenia) and the symptoms can include weakness, fatigue, infections and/or bleedings 
(hemorrhage). The incidence of AML in Norway is approximately 125 new cases per year. 
 
1.1. Diagnosis and classification  
I.  Diagnosis 
The definitive diagnosis of AML requires demonstration of three diagnostic components: 
o The presence of more than 30% (the older The French-American-British (FAB) standard (2, 3)) 
or 20% (the newer WHO standard (4)) leukemic blasts in a bone marrow aspirate. 
o The detection of myeloid differentiation either by histochemistry or by analysis of myeloid 
membrane molecules usually by flow cytometry. 
o Sub-classification according to (i) the FAB that is based on morphology and histochemistry; or 
(ii) a more detailed classification based on morphological characteristics together with clinical 
history (de novo or secondary leukemia) and genetic analysis in accordance with the new WHO 
classification (Table 1). 
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II.  Diagnostic tools 
The infiltration of leukemic blasts in the bone marrow is validated cytologically in a bone 
marrow smear to identify the blasts and highlight their nuclear and cytoplasmic morphology (4). 
AML is a heterogeneous disease and the classification into appropriate variant is a part of the 
diagnosis. According to the morphological FAB classification (2, 3), AML can be divided into eight 
subtypes (M0-M7). The subtypes differ with respect to the myeloid lineage involved and the degree 
of leukemic cell differentiation. Recently, the World Health Organization (WHO) modified the FAB 
classification (4, 5) and grouped AML in four categories; i) AML with recurrent genetic 
abnormalities, ii) AML with multilineage dysplasia, iii) AML and myelodysplastic syndromes 
(MDS), therapy related, and iv) AML, not otherwise categorized (reflecting the old FAB 
classification subtypes M0-M7). The WHO classification is summarized in Table 1. An additional 
group of acute leukemia of ambigous lineage is defined, these are rare leukemias and account for less 
than 4% of all cases of acute leukemia.  
 
Table 1. WHO classification of acute myelogenous leukemia (4, 5). 
 
AML with 
recurrent genetic abnormalities 
o AML with t(8;21)(q22;q22), (AML1/ETO) 
o AML with abnormal BM eosinophils and inv(16)(p13q22) or 
t(16;16)(p13;q22), (CBF/MYH11) 
o APL with t(15;17)(q22;q12), (PML/RAR) and variants 
o AML with 11q23 (MLL) abnormalities 
AML with 
multilineage dysplasia 
o Following MDS or MDS/MPD 
o Without antecedent MDS or MDS/MPD, but with dysplasia in at least 
50% of cells in 2 or more myeloid lineage 
AML and MDS, 
therapy related 
o Alkylating agent/radiation – related type 
o Topoisomerase II inhibitor – related type 
o Others 
AML, 
not otherwise categorized 
AML minimally differentiated 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/acute monocytic leukemia 
Acute erythroid leukemia (erytroid/leukemia and pure erythroid) 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
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Cytochemistry and light microscopy (primarily Wright-Giemsa or May-Grünwald-Giemsa 
staining) is the principle method for the diagnosis and FAB-subclassification of AML (1). To require 
the diagnosis all cases of AML, except M0, must stain positive for MPO and Sudan Black. Other 
stains that can be briefly mentioned are non-specific esterase (AML-M2, M4 or M5) and 
chloroacetate esterase (late myeloblast and early promyelocyte stage AML-M3) (1). 
Immunophenotyping (i.e. flowcytometric analysis of differentiation-associated molecule 
expression) analysis plays a central role especially in separating between minimally differentiated 
acute myeloid leukemia and acute lymphoblastic leukemia (6). Immunophenotyping is generally 
performed by flow cytometry, but also by immunohistochemistry on slides, and the value of 
particular markers may differ depending on the technique. All hematopoietic cells express the 
common leucocyte antigen (CD45) and 40-60% of the cases will express the stem cell marker CD34 
(1). Antigens most frequently used for myeloid lineage assessment are the highly specific myeloid 
antigens CD117 (c-kit) and cytoplasmic myeloperoxidase (cMPO). Other less specific myeloid 
antigens like CD13, CD33 and CD15, can also occur in acute lymphoblastic leukemia (ALL); and 
lymphoid markers like CD2 may also be abberantly expressed in AML (1). In addition to 
determining myeloid lineage, immunophenotyping can identify monocytic, erythroid, or 
megakaryocytic differentiation. Markers related to lineage differentiation include CD14 and CD11b 
in AML-M4 and M5, glycophorin A in AML-M6 and platelet glycoproteins CD41, CD42 and CD61 
in AML-M7 (1).  
Cytogenetic analysis shows that 50-70% of patients with de novo AML have chromosomal 
abnormalities like translocation (t), deletion (del), inversion (inv) or aneuploidy (i.e. abnormal 
numbers of specific chromosomes or chromosome sets) (1). Trisomy 8 is the most common 
numerical cytogenetic abnormalities found in AML. Specific cytogentic abnormalities (i) can be 
closely or uniquely associated with morphology and WHO-classification subsets; (ii) may be 
associated with previous chemotherapy in the WHO-subclasses associated with previous treatment 
with alkylating agents or topoisomerase II inhibitors; and (iii) can have additional diagnostic (t(8;21) 
and inv (16) classified as AML independent of the blast count according to the WHO criteria), 
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prognostic and therapeutic importance. Cytogenetic analysis includes the well-established routine 
analysis of G-Banded chromosomes, as well as molecular cytogenetics such as fluorescent in situ 
hybridization (FISH) and comparative genomic hybridization (CGH). In addition to cytogenetic 
analysis the PCR-based techniques are also applied. 
 
III.  Prognostic features 
If AML remain untreated, most patients will die during days or weeks depending mostly on the 
levels of blasts in the peripheral blood and bone marrow complications. The median survival for 
patients only receiving supportive therapy is only 3-4 months, and only exceptional patients survive 
for more than one year. Complete remission (CR) rates after intensive chemotherapy vary from 10 to 
80%, approximately 10-20% of patients will have refractory disease and first line therapies will fail 
to achieve CR, and 5-20% of those treated will die during induction therapy (see below). This 
treatment-related mortality depends on the age and the general health condition of the patients and 
individuals above 60 years of age will usually not receive the most intensive chemotherapy with 
high-dose cytarabine. A large proportion of those in CR will relapse usually within 1-2 years, and 
their overall survival is less than 10% (1). It is generally accepted that patients with primary 
refractory disease AML relapse after intensive chemotherapy cannot be cured by conventional 
chemotherapy but only by allogeneic stem cell transplantation (7). 
Age is a highly significant prognostic value as prognosis worsens with increased age. This is due 
to the increased treatment-related mortality in elderly patients and an increased frequency of high-
risk karyotypic abnormalities. Response to the initial induction therapy and thus the time taken to 
achieve blast clearance is an important indicator to outcome (1). Failure to clear leukemic blasts by 
day 16 is a poor prognostic marker as reported by the German AMLCG group (8).  
Approximately 60% of AML patients have an abnormal karyotype and this is highly predictive 
of response (9, 10): 
o Approximately 25% of patients have favourable cytogentics, i.e. t(15;17), inv(16), t(16;16) and 
t(8;21). These patients have a 5 year disease-free survival of around 65-80%. 
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o A smaller subset of patients (approximately 10%) will have adverse cytogenetics that include 
aneuploidy (-7, -5-5q), abnormalities of 3q or a complex karyotype. These patients have a 5 year 
survival of 10-20%. 
o The remaining will have intermediate-risk cytogenetics, many of them with a normal karyotype, 
and a 5 year survival of 30-40% (1). 
In-frame internal tandem duplication (ITD) mutations of the Fms-like tyrosine kinase 3 (flt-3), exons 
14-15, have been found in 15-30% of cases of AML. These mutations result in dimerization and 
constitutive activation of the receptor (11). ITD mutations have been shown to be an independent 
poor prognostic factor in several studies (1). In addition, there has been reported a point mutation of 
codon 835 of flt3 in 7-8% of cases of de novo AML (12), resulting in the upregulation of the function 
of the kinase domain. The prognostic significance of the point mutation remains uncertain although 
certain investigators have reported an adverse effect (1). On the contrary of the poor prognosis 
marker ITD-flt3, the mutations of Nucleophosmin (NPM), exon-12, occur in 40-50% of AML with 
normal karyotype and are predictors of favourable prognosis especially for patients without Flt3-ITD 
(13-16).  
Gene expression profiling (GEP) by DNA microarray of AML is becoming more and more 
established and seem to be valuable, not only for diagnosing different cytogenetic subtypes but also 
for discovering novel AML subclasses (17). Several studies have emphasized that gene expression 
signature can be associated with prognosis (17-19).  
 
1.2. The treatment of AML 
 
The initial treatment of AML is remission induction therapy that aims to reduce the leukemic cells to 
below the cytologically detectable level of approximately 109 cells. This treatment is followed by a 
postinduction or “remission consolidation” therapy, consisting of one or more courses of 
chemotherapy or stem cell transplantation. The goal of the postinduction therapy is to eradicate 
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residual leukemia cells and thereby prevent later relapse. The treatment-related mortality is relatively 
low for consolidation therapy with conventional chemotherapy and autologous stem cell 
transplantation, whereas allotransplantation has a higher treatment-related mortality. The decision 
whether or not to recommend an allotransplantation is often based on the following criteria: 
o The cytogentic abnormalities (20) and karyotype (21) of the AML cells and whether they are 
associated with a high/intermediate/low risk of later relapse. 
o The patients age and general health; allotransplatation is usually not recommended for patients 
above 55-60 years of age. 
o Whether an HLA-matched sibling donor is available or an HLA-matched unrelated donor has to 
be used; the transplantation-related mortality is higher when unrelated donors are used. 
 
I.  Remission induction therapy 
The most common induction remission regime is cytarabine given by continuous intravenous 
(IV) infusions (100 mg/m2 per day) for seven days plus daunorubicin (45 to 60 mg/m2 by intravenous 
short-time infusion) daily for the first three days (the “7+3” regimen). Approximately 60 to 80 
percent of patients achieve a CR with this regimen (22-24). Typically, the side effects of this 
treatment are severe bone marrow suppression (myelosuppression), injury of the mucosal lining of 
mouth and throat (mucosities), and diarrhea. Alternative intensification regimen with intensification 
of induction therapy or addition of potentially non-cross-resistant drugs have been explored (25-30), 
but the relative benefits of these strategies or of long-term maintenance therapy are not firmly clear 
(31).  
Supportive care, like transfusions and antibiotics, has reduced treatment related mortality for 
both young and elderly patients. Initial uncontrolled trials using GM-CSF or G-CSF suggested 
decrease in the duration of neutropenia after remission induction chemotherapy (1). However, data 
from more recent large controlled trials are variable (32, 33) and thus does not firmly support the 
previous conclusions drawn from the uncontrolled trials. Other cytokines and growth factors to be 
used as supportive care are under investigation but are not used in routine clinical practice (34).  
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G-CSF has also been used to sensitize (prime) leukemic blasts and thereby increase the 
effects of chemotherapy (35, 36), either through enhanced leukemic cell uptake of chemotherapeutic 
agents (35) and/or by driving resting cells into cell cycle (36). Some of these studies suggest 
improved overall survival in the subset of patients with intermediate-risk karyotypes (37, 38). 
 
II.  Postremission therapy 
In general, there are three choices for postremission therapy: conventional consolidation 
chemotherapy, allogeneic hematopoietic cell transplantation (HCT), or autologous HCT.   
Consolidation chemotherapy can be the same chemotherapy regimen used for remission 
induction or potentially non-cross-resistant drugs. High dose cytarabine (HDAC) seems to provide 
the best survival, at least for good and intermediate prognosis patients (24). This intensive 
consolidation therapy results in significantly longer survival than less intensive maintenance therapy 
alone (true for patients below 60 years of age) and if several courses of consolidation chemotherapy 
are given, survival at two or three years is 35 to 50 percent for young and middle-aged adults who 
have achieved CR (22, 24, 39, 40). HDAC cannot be used for patients above 60 years of age due to 
an unacceptable risk of severe neurological toxicity.  
Bone marrow transplantation usually requires that the recipient’s own bone marrow is 
destroyed (myeloblative therapy) or partly destroyed (nonmyeloblative therapy) prior to 
transplantation. Both peripheral blood mobilized and bone marrow stem cells can be used for 
transplantation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) involves related 
(preferably an human leukocyte antigens (HLA)-identical sibling or an HLA-matched relative) or 
unrelated donor with the same HLA as the recipient. HLA genes can be categorized into two major 
types; Type I (e.g. HLA-A, HLA-B and HLA-C) and Type II (e.g. HLA-DR, HLA-DQB1). If there is 
no complete match, a partially matched donor can be considered. However, this last procedure will 
increase the risk of graft rejection or severe graft-versus-host (GVH) disease. One beneficial 
therapeutic component of allo-HCT is that the donor T cells may produce a specific graft-versus-
leukemia (GVL) immune response, which may contribute to the eradication of remaining leukemia 
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cells. This immune response has been correlated with improved disease-free survival. Long-term 
disease free survival in adult patients receiving allo-HSCT in first CR is approximately 45-65% (41-
46). In contrast, survival following allo-HCT in patients with relapsed AML is 35% or less (47). In 
autologous hematopoietic cell transplantation (auto-HCT) the patients’ own hematopoietic stem cells 
(HSC) are isolated, stored and returned to the body after myeloablative therapy. Treatment-related 
morbidity and mortality are low (5%), thereby allowing it’s use in patients up to 70 years of age, 
while relapse rates are relatively high (30-50%). Overall outcomes after auto-HCT are not clearly 
better than for patients who receive conventional chemotherapy (48-50). 
  
1.3. Additional biological characteristics of the AML cells 
 
Human AML cells are characterized by (i) constitutive cytokine release; (ii) expression of a wide 
range of cytokine receptors, including several hematopoietic growth factors; (iii) expression of 
various adhesion molecules involved in the crosstalk between AML cells, extracellular matrix 
elements and nonleukemic neighbouring cells; (iv) alteration in intracellular signaling pathways, 
especially in pathways involved in regulation of apoptosis (51-54). These biological characteristics 
are probably important for leukemogenesis, and these characteristics also seem to be of clinical 
importance as prognostic parameters: 
o Previous studies suggest that autocrine proliferation, i.e. spontaneous in vitro proliferation due to 
autocrine/spontaneous/constitutive release of growth factors, is an adverse prognostic parameter 
associated with an increased relapse risk and decreased survival (51).  
o The constitutive release of angioregulatory mediators seems to have a prognostic impact. A 
recent publication described that expression of Angiopoietin-2 was associated with a good 
prognosis (55), whereas VEGF release and high systemic levels of the angioregulatory molecules 
VEGF and endostatin seem to be associated with an adverse prognosis (56). 
o Intracellular signaling events seem to affect prognosis: (i) specific intracellular phosphoresponses 
to exogenous cytokines seem to be associated with prognosis (52); and (i) the intracellular 
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balance between pro- and antiapoptotic signaling seem to influence the risk of relapse after 
intensive chemotherapy (54).  
Taken together these observations suggest that leukemogenesis and chemosensitivity depend both on 
intracellular AML cell characteristics as well as the extracellular interactions between AML cells and 
matrix molecules or neighbouring nonleukemic cells.  
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2. The immune system 
 
 
The immune system (57, 58) may be divided into two major compartments; innate immunity that is 
antigen non-specific and adaptive immunity that involves the antigen specific humoral and cellular 
arms of the immune system. However, the innate and adaptive responses are a highly cooperative 
system, increasing the efficiency of immune responsiveness.  
 
2.1. The innate immune system 
 
Innate immunity (59, 60) constitute the antigen-independent immune mechanism generally involving 
i) surface barriers including antimicrobial peptides, ii) mononuclear phagocytes (e.g. monocytes and 
macrophages), iii) polymorphonuclear phagocytes (i.e. neutrophil, eosinophil and basophil), iv) 
natural killer (NK) cells , v) dendritic cells (DCs), and vi) complement activation. NK cells and DCs 
are especially important in tumor immunology and immunotherapy. 
NK cells are lymphocytes capable of both directly killing of target cells and production of 
immunoregulatory cytokines (61, 62). Mature NK cells are primarily found in PB (10-15% of total 
lymphocytes), and typically they express the low affinity receptor for the Fc portion of IgG (CD16), 
CD56 and CD161 (61, 62). Phenotypically distinct NK cell populations have been suggested to 
represent independent subsets specialized to primarily mediate one or more NK cell functions based 
on different levels of spontaneous cytotoxicity or of cytokines produced (61, 62).   
DCs are professional antigen presenting cells (APC) and a central player in all immune 
responses, both innate and adaptive (63). By phagocytosis, endocytosis, pinocytosis, or receptor-
mediated uptake, DCs capture antigens for immune presentation. After capture of the foreign 
material, DCs mature and transport the antigens to lymphoid follicles to deliver it to the B 
lymphocytes and to present antigenic peptides to the T lymphocytes. As a result, the specific immune 
responses are induced (63). In PB, there has been described at least two DC subsets; the myeloid-
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derived CD11c+CD123- DCs (mDCs) and lymphoid-derived CD11c-CD123+ DCs (pDCs). pDC seem 
to support the generation of a TH2 response, while mDCs predominantly support a TH1 response (see 
below) (64-66). 
 
2.2. The adaptive immune system 
 
Humoral (involving B cells) and cell-mediated (involving T cells) immunity constitute the antigen-
dependent immune mechanisms (67).  
 
I.  Antigen processing and presentation  
The function of the APCs is to present the antigen to the B and T lymphocytes. B cells interact 
directly with the antigen, via their cell surface B cell receptor (BCR; consisting of membrane 
immunoglobulin (Ig) and Ig/Igß heterodimer), to differentiate into cells that produce antigen-
specific antibodies (67). Unlike B cells, antigenic peptides are presented to T cells in complex with 
HLA molecules from the major histocompatibility complex (MHC) genome area class I or class II. 
Of the nine classical MHC-genes the HLA-A, B and C genes belong to class I, while six HLA-D 
genes belong to the class II. Generally, class II MHC presents peptides derived from proteolysis of 
extracellular antigens in endosomal-type compartments, while class I MHC presents peptides 
primarily originating from intracellular degradation of proteins in the cytosol (57, 58, 67). 
 
 
II.  T cell maturation  
Progenitor double-negative (CD4-CD8-) T cells from the bone marrow enter the thymus and 
rearrange the T cell receptor (TCR) genes to become TCR+ CD4+CD8- or CD4-CD8+ T cells (the 
majority) or TCR+ CD4+CD8- or CD4-CD8+ T cells (67). Positive selection in the thymus 
eliminates T cells unable to recognize self-MHC (i.e. MHC-restriction) and negative selection 
eliminates thymocytes with high-affinity receptors for self-MHC molecules alone or autoantigen plus 
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self-MHC (i.e. self-tolerance) (67). Less than 5% of T cells in humans are TCR+ T cells. In 
general,  T cells are not MHC restricted, and most do not express the CD4 and CD8 coreceptors.  
T cells seem to recognize epitopes and bind to these in much the same way as immunoglobulin 
receptors of B cells (67).  
 
III.  T helper cells 
The generation of both humoral immune responses (by B cells) and cell-mediated 
cytotoxicity (by cytotoxic T (TC) cells) depends on the activation of CD4+ T helper (TH) cells. Initial 
TH cell activation is initiated by the interaction of the TCR-CD3 complex (68) with the processed 
antigenic peptide bound to a class II MHC molecule on the surface of an APC. TCRs are cell surface 
heterodimers consisting of either disulfide-linked - and - or - and -chains. Each TCR chain is 
composed of variable and constant Ig-like extracellular domains, a transmembrane domain and a 
short cytoplasmic tail. The  TCRs bind peptides-MHC (pMHC) with low affinity (~1-100 µM) 
through complementary-determining regions (CDRs) in their variable domains (69). The interaction 
of the TCR-CD3 complex with the antigenic-peptide MHC molecule is followed by binding of 
coreceptor CD4 to the invariant regions of the MHC molecule, leading to the assembly of a signaling 
complex. CD4-associated Lck, a protein tyrosine kinase, phosphorylates the immune-receptor 
tyrosine-based activation motifs (ITAMs) of CD3 z-chain and thus create a docking site for ZAP70 
(67). ZAP70 then phosphorylates adaptor molecules that recruit components from several signaling 
pathways like PkC-mediated pathways, CA2+- mediated pathways and small G-protein mediated 
pathways like Ras and Rac. Finally, these events lead to changes in gene expression by several 
transcription factors (i.e. NFAT, NF-kB, and Elk) (67).  
Naive cells require more than the initial interactions, described above, to be fully activated 
and subsequently proliferate into effector cells. An antigen nonspecific co-stimulatory signal is 
provided by interactions between CD28 on the T cell and members of the B7 family (B7-1 and B7-2) 
on the APC. The ligands for B7 are CD28 and CTLA-4 (CD152) which both are expressed on T cells 
and act antagonistically (67). That is, signaling through CD28 delivers a positive co-stimulatory 
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signal to the T cell while signaling through CTLA-4 is inhibitory and down-regulates the activation 
of T cells. If CD28 co-stimulatory signaling occurs, T cells are triggered into G1 phase of the cell 
cycle, transcription of the gene for IL-2 and the -chain of the high-affinity IL-2 receptor (CD25) are 
induced. The subsequent secretion of IL-2 and its binding to the IL-2 receptor induces the activated 
naive T cells to proliferate and differentiate into long-lived memory or short-lived effector T cell 
populations (67). TH CD4+ effector cells form two subpopulations: the TH1 subset (IL-12R12+) 
secretes IL-2, IFN and TNF-, and generally aid the activation of cytotoxic T lymphocytes, while 
the TH2 subset (IL-12R1+) secretes IL-4, IL-5, IL-6 and IL-10, and is generally important as helper 
cells for B cell activation (57). The cytokines produced by the two subsets also have a cross-
regulatory role, i.e. cytokines secreted from activated TH2 cells will down-regulate the TH1 cells in the 
neighborhood and vice versa (67). 
 
IV. Cytotoxic T cells 
CD8+ T cells recognize antigen presented by MHC class I and function as TC cells (67). 
Activation of resting TC involves first of all TCR stimuli and then secondly stimulation with 
cytokines, especially IL-2, most probably from activated TH cells. Naive TC does not express IL-2 
receptors on their surface but antigen stimulation increases the expression of the IL-2 receptor and 
ensures that only the cells recognizing the antigen will become activated (67).  
Like the CD4+ TH1 and TH2 subsets, effector CD8+ T cell subsets can also be identified; TC1 
and TC2 (70) . The proximal signal for inducing TC1 and TC2 seem to be IL-12 and IL-4 cytokines, 
respectively. The CD8+ T cell subsets are suggested to differ in homing as TC1 is found to express CC 
chemokine receptor 5 (CCR5) and TC2 express CCR4 (70). 
Cytokine-induced killer (CIK) cells are a unique and rare (1-5% in uncultured PBMC) 
population of cytotoxic T lymphocytes with a characteristic CD3+CD56+ phenotype. CIK cells are 
non-MHC-restricted in target cell recognition and killing (71). 
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V.  Regulatory T cells 
 Tolerance is generally divided into central and peripheral tolerance (72). Central tolerance is 
the clonal deletion and inactivation of self-reactive immature lymphocytes during differentiation (see 
above). Peripheral tolerance concerns mature circulating lymphocytes and it is proposed that 
regulatory T cells are responsible for inducing and maintaining peripheral tolerance. The classical 
regulatory T cells are the thymus-derived CD4+CD25+FOXP3+ Treg cells. However, several 
phenotypically distinct regulatory T-cell populations of both CD4+ and CD8+ subset have been 
suggested. Possibly, Treg cells can mediate tolerance by suppressing self-antigen-reactive T cells by 
various mechanisms, including: 
o inducing B7-H4 expression by APCs, which in turn induce T cell cycle arrest through B7-H4; 
o directly killing of target cells such as T cells and APCs through perforin- or granzyme B-
dependent pathways; 
o CTLA4+ Treg cells can induce indoleamine 2,3-dioxygenase (IDO) expression by APCs which in 
turn suppress T cell activation by reducing tryptophan; 
o Release of IL-10 and transforming growth factor (TGF) and thereby direct inhibition of T cell 
activation and suppression of APC function by decreasing their expression of MHC molecules, 
CD80, CD86, and IL-12 (72). 
 
VI. B cells 
Antigen-independent maturation of B cells, involving Ig gene rearrangements, occurs in the 
bone marrow and generates mature naive B cells expressing membrane IgM (mIgM) and mIgD with 
a single antigenic specificity (67). During maturation, the self-reactive B cells are eliminated by 
negative selection. The activation, proliferation and differentiation of naive B cells occur in the 
periphery and require the presence of antigen. The antigen recognition molecule of the B cell is the 
surface Ig that associates with the heterodimer Ig-/Ig-, thus forming the BCR. The B cell co-
receptor (complex of CD19, CD21 and CD81) provides stimulatory modifying signals that enhance 
B cell responses. B cell activation through antigen binding to BCR, can occur by two different routes 
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depending on the nature of antigen, one route is dependent on TH cells and the other is not. Antigens 
that can activate B cells in the absence of direct interaction with TH cells are known as thymus-
independent (TI) antigens. TI antigens can be further divided into two groups; (i) TI-1 antigens that 
are truly T cell independent and give a weaker response with no memory cells formed and IgM as the 
predominant antibody; and (ii) TI-2 antigens that require TH cytokines both for efficient B-cell 
proliferation and for class switch to isotypes other than IgM. The B cell response to thymus-
dependent (TD) antigens requires the direct contact with TH cells. The TD-antigens bind to mIg on B 
cells and become internalized by receptor-mediated endocytosis, processed into peptides, and 
presented in MHC class II molecules. Once TH cells recognize the MHC-peptide, the two cells form a 
T-B conjugate. This leads to TH cell cytokine release as well as upregulation of CD40L to provide an 
essential signal for T cell dependent and antigen-specific B cell activation. Once activated, B cells 
begin to express membrane receptors for IL-2, IL-4, IL-5 as well as other cytokines. These receptors 
bind the TH cytokines and thus induce differentiation with Ig class switching and development of 
antibody-secreting plasma cells, memory B cells and affinity maturation (67).
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3. The immune system in AML patients 
 
It is well known that AML patients are immunocompromized and have an increased risk of 
infections. These patients often have neutropenia initially due to the disease and later eventually due 
to intensive chemotherapy. However, as will be seen from the studies reviewed below these patients 
can also have other disease- or therapy-induced immune dysfunctions. One would in addition expect 
that there will be differences between patients due to for example differences in chemotherapy 
regimen, different AML cell phenotypes and age-dependent alterations of the immune system.  
 
3.1. The immune system in untreated AML 
 
I. Cellular innate immunity in AML 
 
Elevated levels of cells with NK phenotype have been found in AML (73). The CD3-CD56+ 
NK cells were found significantly increased at diagnosis both in the blood and bone marrow. In 
contrast, CD16+CD2+ and CD16+CD2- NK cells were only increased in the blood whereas there were 
normal levels in the bone marrow. When the authors divided the AML cases into two groups 
according to the absolute number of circulating NK cells, the patients with the highest levels also 
showed an increased proportion of circulating leukemic blasts. In contrast to elevated NK cell levels, 
several other studies report of NK cell dysfunction (74-76) or impeded NK cell maturation (77) in 
patients with cancer and leukemia. In addition, it has been suggested that leukemic cells display a 
more inhibitory AB killer cell immunoglobulin-like receptor (KIR) phenotype, compared to healthy 
controls, in favor of escape from NK cell immunity (78). It is difficult to make a firm conclusion 
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from these studies, but it is justified to state that both qualitative as well as quantitative disturbances 
in the NK cell system can be detected in cancer patients and probably also in AML patients. 
DCs are central in the presentation of tumor antigens to the adaptive arms of the immune 
system. There are several reports of DC defects in cancer patients (reviewed in (79)). Abnormal 
frequencies as well as abnormal differentiation and/or maturation possibly caused by tumor derived 
factors, are some of the dysfunctions described (79). A number of studies throw light on the 
generation of leukemic DCs in the context of immunotherapy, but there are few studies describing 
the remaining normal DCs in AML. Mohty et al. (80) reported a quantitative imbalance in circulating 
blood myeloid DCs (MDCs) and plasmacytoid monocytes (PDCs) in 70% of the AML patients.  
 
II. Cellular immunity in AML 
 
Altered ratios of TH1 versus TH2 or TC1 versus TC2 cells have been observed in several 
malignancies (81-90). However, a general decreased T cell number without such shifts has also been 
reported (91, 92), as well as close to normal or increased T-cell numbers (93, 94). A possible 
explanation for this variation is that there are differences between malignancies and possibly also 
between individual cancer patients.  
An abnormal CD4:CD8 ratio has been reported in several malignancies, and this can be due 
to increased or decreased absolute levels of CD8+ cells (95-97) and/or increased or reduced levels of 
the CD4+ cells (97-99). In patients with head and neck cancer increased CD4:CD8 ratio was observed 
in lymph node lymphocytes versus tumor-infiltrating lymphocytes and peripheral blood lymphocytes 
(PBLs). In these cases the aberrant ratio was attributable to both a significant enrichment in CD4+ T 
cells as well as a decrease in CD8+ T cells (97). In contrast, analysis of patients with non-small cell 
lung cancer revealed that tumor infiltrating lymphocytes displayed a lower CD4:CD8 ratio than the 
PBLs (100). In peripheral blood of patients with multiple myeloma the percentage of CD3+ and CD8+ 
cells was within the normal range while the percentage of CD4+ cells was slightly reduced for a small 
subset of patients. On the contrary, in bone marrow of myeloma patients the percentage of CD4+ was 
profoundly reduced, leading to an altered CD4:CD8 ratio in all multiple myeloma patients (99).  
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There are some studies suggesting that cancer patients have more memory and less naive T 
cells applicable for PBL or tumor infiltrating lymphocytes or both (101-104). In hematological 
malignancies there has also been suggested decreased memory T helper cells (105, 106).  
There are a few reports regarding the T lymphocyte subsets in patients with de novo AML. 
Vidriales and colleagues (73) reported (i) increased T lymphocytes with NK activities (CD3+CD56+) 
in PB but normal levels in BM, (ii) normal distribution of CD4+CD45RA+ (putative naïve) and 
CD4+CD29+ (putative memory) cells in the PB, and (iii) increased distribution of the cytotoxic subset 
CD8+CD57+ within the CD8+ cells (73). A more recent report (107) outlined that the absolute 
numbers of CD8+ and CD8- (putative CD4+) CD3+ T cells in whole blood of 13 patients with AML 
were similar to those of healthy controls. However, there was a tendency of higher numbers of CD8+ 
T cells in the patients compared with healthy controls, which was also mirrored in the lower 
CD4:CD8 ratios (107). These investigators (107) also measured the intracellular cytokine levels of 
the whole-blood lymphocytes in the absence of in vitro stimulation. They did not find any significant 
changes in the IL-4, IL-10, IL-12 or IFN levels in the cell subsets derived from AML patients 
compared with healthy individuals and thus suggesting normal TH1 and TH2 profile. However, a trend 
towards higher absolute numbers and percentages of CD8+ and CD8- lymphocytes with detectable IL-
10, IL-12 and IFN was observed for the AML patients compared with the healthy controls. Again it 
is difficult to reach a firm conclusion, and this is partly due to the question of patient heterogeneity 
and the low number of patients in some of the studies.  
 Treg cells control autoimmune T cell reactivity in the periphery and may also suppress 
immune responses against cancer cells (72). An increased number of Treg cells has been reported for 
patients with ovarian cancer, lung cancer, breast cancer, gastrointestinal malignancies and lymphoma 
(108-114). Wang et al. reported significantly higher proportions of CD4+CD25high Treg cells in AML 
patients compared with healthy controls (115). These cells were (i) CD45-RA-, CD69-, CD45-RO+, 
CD95+, intercellular CTLA-4+ ; (ii) secreted low levels of TNF- and IL-10 and did not release IL-2, 
IL-4, IL-5 and or IFN; and (iii) behaved as Treg cells by inhibiting CD4+CD25- T cell proliferation 
and cytokine production during in vitro activation (115). 
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III. Humoral immunity in AML 
 
There are sporadic reports of spontaneous remission (SR) of cancer, including leukemia and 
myelodysplasia (116, 117), often but not necessarily following bacterial infections or blood 
transfusions (118). Some authors have suggested that the mechanism leading to SR is an underlying 
humoral immunologic response (116), although there are also other possibilities (119, 120). 
However, spontaneous remission in cancer is rare, despite the presence of naturally serum antibodies 
against tumor-associated antigens (TAAs) in 14-31 per cent of patients (121). It is not known why 
these antibodies against cancer are not more effective. On the other hand, the use of antibody therapy 
in cancer treatment suggests that cancer-reactive antibodies can mediate strong anti-cancer effects 
(122). However, despite the encouraging experience with antibody therapy in certain malignancies it 
is at present hard to believe that humoral immune responses alone can be responsible for spontaneous 
remissions in cancer patients. 
There is an expanding list of autoantibodies against tumor-associated antigens (TAAs) that 
can be detected in cancer patients, including anti-oncoprotein (HER-2/neu), anti-tumor suppression 
antigen (P53), anti-proliferation associated antigens (cyclin A, cyclin B1, and CDKs), anti-
onconeural antigens (Hu, and Yo), and anti-cancer/testis antigens (NY-ESO-1 and MAGE-1), and 
others (see (123) for review). The identification of a cancer autoantibody signature may become 
useful as a diagnostic and prognostic specimen (124-126), but their possible role in the immune 
defence against cancer need to be further investigated.  
The number of autoantibodies known to occur in AML patients is few compared to other 
malignancies. However, autoantibodies against the following antigens have been detected at an 
increased frequency in AML patients compared with healthy controls: Wilms tumor gene product 
(WT1) (127, 128), single-stranded DNA (129), anticardiolipin antibodies (ACA) (130), the M-phase 
phosphoprotein 11 (MPP11) (131), receptor for hyaluronan acid-mediated motility (RHAMM) (132), 
MAZ (133), PASD1 (134), and Rhamm-like protein (135). Such antibodies have been reported for 20 
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to 100 per cent of the AML patients examined. Some of these autoantibodies have been detected in 
either conditions associated with tissue destruction such as systemic lupus erythematosus (SLE) 
(ssDNA) (129) or infections (ACA) (130). Some studies have in addition reported the disappearance 
of autoantibodies in AML patients when they reach hematological remission (128, 136), possibly as a 
consequence of a lower AML cell burden and decreased antigenic stimulation leading to decreased 
autoantibody production. 
 
IV. Leukemia derived factors affecting the immune system 
 
Numerous immunosuppressive factors like TGF-, IL-10, vascular endothelial growth factor 
(VEGF) and sFas-L have been detected in tumor micoenvironments (137). Such tumor-derived 
factors can for instance induce apoptosis in T cells (138-140) or inhibit a Th1 response (141) and 
thereby contribute to local immunosuppression. The AML microenvironment has also been shown to 
inhibit T cell cytotoxic activity (142, 143), and AML culture supernatants show a TGF-, IL-10 and 
VEGF independent inhibition of T cell activation, T cell proliferation and Th1 cytokine production 
(143). AML supernatants have also been shown to affect major signaling pathways involved in T cell 
activation and proliferation;  
o reduced nuclear translocation of NFATc and NF-B;  
o delayed activation of c-Jun N-terminal kinase 1/2;  
o no phosphorylation of pRb, cyclin-dependent kinase 6/4-cyclin D, and of p130 was found;  
o no induction of c-Myc, cyclin D3, and p107. 
However, calcium mobilization, extracellular signal-regulated kinase 1/2, p38, and STAT5 remained 
unaffected (143). 
Misoguchi et al. (144) were the first to suggest that immune dysfunction in cancer patients 
was due to an altered composition of the T-cell receptor signaling complex. Today, decreased 
expression of  CD3-  (CD3- zeta) in T cells have been demonstrated in several malignancies (145-
148). Reduced CD3- expression in tumor infiltrating lymphocytes even seems to be an independent 
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prognostic factor for patients with oral carcinoma (149). Furthermore, Buggins et al. (150) reported 
abnormal expression of CD3- in 64 % out of 46 myeloid leukemia patients examined (of which 11 
were acute) and successful remission induction was associated with recovery of CD3- expression. 
Moreover, the CD3- associated protein tyrosine kinases (p56lck, p59fyn, and ZAP-70) showed 
variable but often reduced expression in these patients (150). Finally, in a murine AML model (151) 
there were seen reduced responses (proliferation and IL-2 secretion) to mitogenic anti-CD3- but not 
to PMA/ionomycin (which is TCR independent) as early as one week following the injection of 
leukemic cells, whereas loss of CD3- protein expression and signaling abnormalities (calcium 
mobilization and tyrosine kinase activity) were detected only in advanced disease (4 weeks after 
injection). It was also shown in vitro that leukemia-derived factor(s) stimulated splenic macrophages 
to secrete a second soluble factor(s) that caused the loss of CD3- (151). Thus, altered intracellular 
signaling during T cell activation probably contributes to the immunodeficiency in AML. 
 
3.2. The immune system in AML patients after chemotherapy  
 
I. Effects of conventional chemotherapy on the cellular immune system  
 
Patients receiving conventional intensive chemotherapy or myeloblative treatment prior to auto-SCT, 
encounter a post-treatment period of severe cytopenia, including T lymphopenia (152, 153). 
Hematopoietic reconstitution (neutrophils, monocytes, platelets) often occurs relatively early after 
chemotherapy compared  with lymphoid reconstitution (153).  
For patients receiving conventional chemotherapy most peripheral leukocytes are T 
lymphocytes, whereas B lymphocytes and monocytes show a wide variation among patients and 
usually represent less than 10% of the cells (154). Most of the circulating T cells in these patients 
express the activation markers HLA-DR as well as CD25 and CD69 (153). Following chemotherapy 
there seems to an absence of CD45RA+CD4+ T cells, all the remaining CD4+ T cells expressed the 
CD45RO+ isoform (152, 153).   
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There has also been some reports regarding functional evaluation of T cells, these have 
included the examination of cytokine release and cytokine responsiveness of the in vitro expanded 
clonogenic T cell minority derived from AML patients with therapy-induced cytopenia (155-159). 
Circulating CD4+ and CD8+  TCR+ T cells include a minor subset of clonogenic cells (155) that 
secrete a range of immunoregulatory cytokines (156). The frequency of these clonogenic T cells is 
often reduced compared to healthy individuals (155).  
Reports of functional analysis of peripheral T cells other than the clonogenic minority are 
scarce. However, there are a few studies regarding the proliferative response of T cell derived from 
patients with leucopenia evaluated in a whole blood assay (154, 160). In this assay T cells were 
found to have proliferative responsiveness equal to healthy controls in the presence of optimal 
costimulation with anti-CD3 + anti-CD28, but responses were significantly reduced in the AML 
patients with anti-CD3 stimulation only. Furthermore, the responses were significantly lower for 
ALL than for the AML patients (154).  
Patients receiving chemotherapy for malignant disorders seem to develop a CD4+ T 
lymphopenia together with high serum level of the pleiotropic cytokine IL-7 (161, 162). In contrast, 
patients with untreated AML and severe chemotherapy-induced leucopenia with CD4+ T 
lymphopenia showed decreased IL-7 serum levels, and the detection of circulating IL-7-responsive T 
cells indicated that variations in systemic IL-7 levels are functionally important and may contribute 
to an additional qualitative T cell defect in T lymphopenic AML patients (163). Other studies have 
demonstrated that administration of recombinant interleukin-7 to humans could selectively increase 
total CD4+ and CD8+ T lymphocytes together with decrease in the percentage of CD4+ Treg cells 
(164). 
Very few studies have examined the T cell system in AML patients after hematopoietic 
reconstitution. Long-lasting T cell defects can occur after intensive chemotherapy for other 
malignancies, especially in adult patients (152). One would expect that similar effects may occur 
after AML therapy.  
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II. The immune system after autologous and allogeneic stem cell 
transplantation  
 
The recirculation pattern of leukocyte subpopulations during the first 24h after auto-HSCT differs 
between leukocyte subsets (165). The number of CD3+ T lymphocytes increased during this period, 
whereas CD56+ NK cells decreased rapidly and remained low throughout the observation period. B 
lymphocyte levels were also low during the observation period (165). The early reconstitution of T 
lymphocyte response after both auto- and allo-BMT is mainly due to the peripheral expansion of 
mature T cells transferred with the graft (166, 167). The recovery of polyclonal T lymphocytes 
occurs gradually, and complete reconstitution of humoral and cellular immunity may take more than 
one year (168). Similar to the observations in patients only receiving intensive chemotherapy, there 
seem to be an absence of CD45RA+CD4+ T cells early after auto-transplantation with a remaining 
population of CD4+CD45RO+ circulating T lymphocytes (152, 153, 169). One study has suggested 
that BM-resident memory T cells are resistant to both pretransplant chemotherapy and ex vivo 
pharmacological purging and thus may contribute to the immune reconstitution after auto-BMT 
(170). 
The studies in this thesis did not include allografted patients and thus a detailed review of 
reconstitution after allografting is therefore not included in this presentation. Anyhow, recently, the 
CD4+ helper T cell recovery after allo-HSCT have been characterized for patients with various 
hematological malignancies (171). In short, the early recovery of CD4+ T cells at 3 months was a 
favorable prognostic factor together with higher CD34+ cell transplant dose in terms of overall 
survival and non-relapse mortality (171). Also, early immune recovery has been suggested enhanced 
following blood stem cell allografting compared with BM allografting (172).  
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Aims of the thesis 
 
New and less toxic therapeutic strategies are needed to improve survival after chemotherapy and also 
as an alternative to chemotherapy for elderly patients, and for this reason immunotherapy is 
considered in AML. A characterization of the immune system in AML patients is therefore important 
as a basis for the design of clinical therapeutic approaches.  
 
The aims of the studies were: 
o to characterize the circulating T cells in patients with untreated AML  
o to further characterize the remaining T cells in AML patients receiving intensive chemotherapy, 
including the T cell release of IFNγ as well as other cytokines known to affect primary human 
AML cells 
o to characterize in detail the functional effects of the T cell derived cytokine IFN on primary 
human AML cells for a large group of consecutive patients 
o to investigate the humoral immune response against autoantigens in AML patients, including a 
more detailed investigation of whether cyclin B1 should be regarded as a leukemia-associated 
antigen in AML 
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Methods and subjects 
Unless otherwise stated we included unselected patients in our studies, i.e. either randomly selected 
patients or consecutive patients. For our studies of AML cells we investigated cells that were stored 
frozen in liquid nitrogen. The advantage of this approach are that (i) cells from the same patient can 
be available for several experiments; (ii) an extensive biological characterization is possible; and (iii) 
large groups of patients can be investigated within a reasonable time and in the same experimental 
setup. However, two major disadvantages are present: the cells have a decreased viability after 
storage and even the viable cells have alterations especially in the membrane molecule expression 
(173-176)  
 
Our in vitro cultures were usually prepared in serum-free medium (177). However, we regard the 
serumfree Stem Span medium as suboptimal for fibroblasts, osteoblasts and bone marrow stromal 
cells (178) and for this reason cocultutures of AML cells and these nonleukemic cells were prepared 
in serum-containing Stem Span as described in these studies. 
 
When investigating T cell responses for patients with chemotherapy-induced cytopenia we used a 
whole blood assay that has been characterized in detail in previous studies (154, 160). The cells were 
then activated by using well-characterized T cell stimulatory signals. The major disadvantage of this 
assay is that the number of T cells per culture well is not determined. The major advantage is that 
relatively large experiments can be designed even when only small blood samples can be collected. It 
can be argued that the use of a whole blood assay is a disadvantage because the culture conditions 
will differ between patients, e.g. autologous serum is included in the cultures and the number of other 
cells in peripheral blood will differ. On the other hand, it can also be regarded as an advantage that 
the immunocompetent cells are investigated in their natural immunoregulatory network by using 
diluted whole blood.  
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Summary of the results 
Paper I 
 
Ersvaer E, Hampson P, Wendelbo O, Lord J, Gjertsen BT, Bruserud O. Circulating T cells derived 
from patients with untreated acute myelogenous leukemia are heterogeneous and can be activated 
through the CD3/TCR complex (2006) 
 
 
Objectives. T lymphocyte defects may contribute to the immune defects in acute myelogenous 
leukemia (AML). We characterized the T cell system for a large group of untreated AML patients.  
 
Methods. T lymphocyte subsets were analyzed by flow cytometry for 45 patients. The in vitro 
interferon (IFN) γ release in response to stimulation with anti-CD3 + anti-CD28 in the presence of 
autologous AML cells was examined for 32 consecutive patients.  
 
Results. The majority of circulating lymphocytes were CD3+ T cell, and CD19+ B cells usually 
constituted <10% of the lymphocytes. Most T cells expressed the αβ T cell receptor (TCRαβ+), and 
only a minority of the cells was TCRγδ+. Both CD4+ and CD8+ T cells were detected, the CD4:CD8 
ratio showed a wide variation but was usually >1.0. The majority of CD4+ T cells were CD45RA+, 
whereas most CD8+ T cells were CD45R0+. The T cells could be stimulated to release interferon-γ 
(IFNγ) in response to anti-CD3 + anti-CD28 even in the presence of excess autologous AML blasts, 
and for a subset (15 of 45) of patients these IFNγ levels could be further increased by the protein 
kinase C (PKC) δ agonist Pep005.  
 
Conclusions. Circulating T cells in patients with untreated AML are mainly CD4+ or CD8+ TCRαβ+; 
both CD45RA+ and CD45R0+ can be detected, and these cells can be activated through the CD3/TCR 
complex even in the presence of excess AML cells. For a subset of patients the T cell responsiveness 
can be further increased by targeting PKC. 
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Paper II 
 
Ersvaer E, Hampson P, Hatfield K, Ulvestad E, Wendelbo O, Lord J, Gjertsen BT, Bruserud O. T 
cells remaining after intensive chemotherapy for  acute myelogenous leukemia show a broad 
cytokine release profile including high levels of interferon- that can be further increased by protein 
kinase C agonist PEP005. (2006) 
 
 
Objectives. Several cytokines are released during T cell activation, including the potentially 
antileukemic interferon-γ (IFNγ) and the hematopoietic growth factor granulocyte-macrophage 
colony-stimulating factor (GM-CSF) that enhance proliferation and inhibit apoptosis of acute 
myelogenous leukemia (AML) cells. In the present study we investigated the release of IFNγ and 
GM-CSF by circulating T cells in AML patients with chemotherapy-induced cytopenia.  
 
Methods. T cells were activated with anti-CD3 plus eventually anti-CD28, and the cells were 
investigated in a whole blood assay in the presence of their natural cytokine network. We examined 
63 samples derived from 16 AML patients during 28 chemotherapy cycles. Activation potential of 
protein kinase C agonist Pep005 was also explored. 
 
Results. Activated T cells showed a broad cytokine release profile, but IFNγ and GM-CSF levels 
showed a significant correlation and were generally higher than the other cytokine levels. IFNγ and 
GM-CSF levels were associated with high CD4:CD8 ratio, low age and no ongoing chemotherapy, 
whereas duration of neutropenia or kind of chemotherapy were not similarly associated. The levels of 
both cytokines were lower than for healthy controls but higher than for multiple myeloma patients 
with cytopenia following autotransplantation. The cytokine levels could be further increased by the 
protein kinase C agonist Pep005.  
 
Conclusions. We conclude that remaining T cells after intensive AML therapy show a broad 
cytokine release profile including high and significantly correlated levels of potentially antileukemic 
IFNγ and the AML growth factor GM-CSF. The final effect of an AML-initiated T cell cytokine 
response will then depend on the functional characteristics of the AML cells because the distribution 
of IFNγ and GM-CSF receptors differ between AML cells of different patients. 
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Paper III 
 
Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud O. Effects of interferon gamma on native 
human acute myelogenous leukaemia cells (2006) Cancer Immunol Immunother. Apr 13; [Epub 
ahead of print] 
 
 
Objectives. T cell targeting immunotherapy is now considered as a possible strategy in acute 
myelogenous leukemia (AML), and IFNγ release may then contribute to the antileukemic effects. We 
investigated effects of IFNγ on native human AML cells.  
 
Methods. The expression of IFNγ receptor  chain and intracellular Stat and Erk1/2 phosphorylation 
after IFN stimulation were analyzed by flow cytometry. Exogenous IFN was added to in vitro 
cultures of AML blasts, and the effect on proliferation (3H-thymidine incorporation), apoptosis 
(Annexin-V and PI) and cytokine release (ELISA) was measured 
 
Results. Normal T cells could be activated to release IFNγ in the presence of AML cells. 
Furthermore, high levels of CD119 (IFNγ receptor  chain) expression were observed for all 39 
patients examined. Receptor expression was decreased after exposure to exogenous IFNγ, and 
receptor ligation caused Stat1 phosphorylation but no phosphorylation of the alternative messengers 
Erk1/2. The effect of exogenous IFNγ on AML blast proliferation was dependent on the local 
cytokine network and IFNγ (i) inhibited proliferation in the presence of exogenous IL1β, GM-CSF, 
G-CSF and SCF; (ii) had divergent effects in the presence of IL3 and Flt3 (65 patients examined); 
(iii) inhibited proliferation in the presence of endothelial cells but had divergent effects in the 
presence of fibroblasts, osteoblasts and normal stromal cells (65 patients examined). IFNγ increased 
stress-induced (spontaneous) in vitro apoptosis as well as cytarabine-induced apoptosis only for a 
subset of patients. Furthermore, IFNγ decreased the release of proangiogenic CXCL8 and increased 
the release of antiangiogenic CXCL9-11.  
 
Conclusions. We conclude that IFNγ can be released in the presence of native human AML cells and 
affect AML cell proliferation, regulation of apoptosis and the balance between pro- and 
antiangiogenic chemokine release. 
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Paper IV 
 
Ersvaer E, Bertelsen LT, Espenes LC, Bredholt T, Boe SO, Iversen BM, Bruserud O, Ulvestad E, 
Gjertsen BT. Characterization of ribosomal P autoantibodies in relation to cell destruction and 
autoimmune disease (2004) Scand J Immunol. Jul-Aug;60(1-2):189-98 
 
 
Objectives. Autoantibodies against the ribosomal P proteins are related to cell death and tissue 
destruction and are frequently exhibited in patients with systemic lupus erythematosus (SLE). We 
attempted to explore the effect of tissue destruction on the induction of anti-P autoantibodies and 
analysed antibody levels for patients with autoimmune disorders and acute myelogenous leukemia 
patients. 
 
Methods. We searched for anti-P autoantibodies by enzyme-linked immunosorbent assay in 201 
antinuclear antibody (ANA)-positive individuals, in 10 patients with treated kidney SLE and in 45 
untreated acute leukaemia patients. The autoantibody reactivity was further characterized using one- 
and two-dimensional immunoblot analysis and immunofluorescence.  
 
Results. Anti-P were detected in 5.5% (11/201) of ANA-positive individuals, but not in kidney-
affected SLE patients or in patients with leukaemia. Seven of 11 anti-P-positive patients had SLE 
(3/11), primary Sjogrens's syndrome (1/11) and other autoimmune diseases (3/11). An association 
between disease activity and anti-P was suggested by follow-up examinations in one SLE patient, 
supported by the absence of anti-P autoantibodies in the 10 treated kidney SLE patients. Anti-P 
autoantibodies were detected by immunoblot in one patient with SLE indicating anti-P2 
predominance and in the patient with Sjogrens's syndrome indicating anti-P1 predominance. 
Diverging humoral responses in these ANA- and anti-P-positive patients were further illustrated by 
immunofluorescence, elucidating varying nuclear reactivity and anti-P pattern. Anti-P could not be 
detected for any leukemia patients before therapy; a smaller patient group was also investigated 
following intensive chemotherapy but anti-P could not be detected for these patients either. 
 
Conclusion. The observation of anti-P in individuals with active autoimmune disease, but not in 
patients with chemotherapy-induced cell damage, suggests that anti-P antibodies are part of a specific 
disease process, and not elicited as a response to cell destruction per se. 
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Paper V 
 
Ersvaer E, Zhang JY, McCormack E, Anensen N, Tan EM, Gjertsen BT, Bruserud O. Cyclin B1 is 
commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and 
serves as a leukemia associated antigen associated with autoantibody response in a subset of 
patients (2006). 
 
 
Objectives. Cyclin B1 is involved in cell cycle regulation of both normal and malignant cells. 
Cytoplasmic expression of cyclin B1 in epithelial malignancies is associated with a specific T cell 
response and presumably also a humoral immune response. We therefore investigated the protein 
expression of cyclin B1 in native human acute myelogenous leukemia (AML) cells and the 
occurrence of cyclin B1 specific antibodies in AML patients.  
 
Methods. Level of intracellular cyclin B1 expression was measured by flow cytometry, while 
confocal laser microscopy indicated the cyclin B1 localization within the naive and dendritic AML 
cells. Serum antibodies were analyzed by ELISA. 
 
Results. AML cell expression of cyclin B1 was detected for all 42 patients investigated by flow 
cytometry; but the percentage of cyclin B1 positive cells showed a wide intra patient variation. 
Confocal laser microscopy demonstrated that most of these patients (32/42-76%) showed abnormal 
cytoplasmic expression. Furthermore, both cytoplasmic and nuclear expression was maintained after 
14 days of in vitro culture and differentiation of the AML cells in the direction of a dendritic cell 
phenotype. AML engraftment in NOD/LtSz-Prkdcscid/B2m-/- mice showed no clear correlation with 
cyclin B1 expression. Cyclin B1 specific serum antibodies could be detected for 8 out of 66 
consecutive patients with untreated AML. Fourteen of these patients of these patients were in 
addition tested later following intensive chemotherapy; three of them had detectable antibody levels 
that decreased following treatment. 
 
Conclusions. Our studies demonstrate that primary human AML cells show aberrant cytoplasmic 
expression of cyclin B1 for a majority of patients; this expression pattern has been associated with 
induction of specific immune responses in patients with epithelial malignancies and a specific 
humoral immune response was also detected for a subset of patients with untreated AML. 
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General discussion 
 
The bone marrow as an immunological compartment  
AML is a bone marrow disease, and the bone marrow is a part of the lymphocyte 
recirculation network. Recently the bone marrow was described in mice to function as a secondary 
lymphoid organ, providing a microenvironment for priming of T cell responses (179). Naive T cells 
can thus home to the bone marrow as a part of their normal recirculatory pathway and become 
primed by CD11c+ dendritic cells in the stroma to generate primary and memory T cell responses 
(179). These observations are further supported by a study describing a secondary in vivo bone 
marrow T cell response induced by a tumor cell vaccine of mice (180). By using peptide/MHC-
tetrameric complexes clonal expansion of antigen-specific T cells could be detected during the 
primary response in BM and during the secondary response in the peritoneal cavity and BM (180). 
Feuerer et al. have also shown that BM stroma in mice constitutively expressed ICAM-1, VCAM-1, 
MadCAM-1, and P-selectin adhesion molecules relevant for homing of blood T lymphocytes to the 
bone marrow, and also bone marrow expression of the T cell co-stimulatory molecule CD80 (181). In 
the same study, CD3+ T cells were detected together with BM resident CD11c+ DCs, often enriched 
in follicle-like structures in the BM parenchyma. Interactions between transferred antigen specific 
transgenic CD4+ T cells and antigen loaded BM-DCs then formed multicellular clusters in situ in 
BM, generated lymphoblasts and lead to clonal T cell expansion within such clusters. The great 
majority of BM-CD4+ T cells had a memory phenotype suggesting that the BM microenvironment 
facilitates maintenance of CD4+ memory (181). 
As the bone marrow of patients with AML will be severely compromised by the presence of 
large numbers of AML blasts, it is possible that reduced T cell responsiveness in this environment 
could contribute to the immunodeficiency that accompanies AML.  
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IFN-γ in patients with AML 
IFN (182) is a lymphokine released especially by activated TH1, TC1 and NK cells. Binding of IFN 
to the IFN receptor complex on target cell transmits signals to the cytoplasm and nucleus through 
the Jak-Stat1 mechanism as well as Stat1 independent pathways (183, 184). In a recent study it was 
demonstrated that intracellular signaling events after IFN receptor ligation could be used in 
prognostic classification of AML patients (52). In the in vitro culture experiments exploring the 
effects of IFN on AML blasts (paper III), we showed that exogenous IFNγ could affect AML cell 
proliferation, regulation of apoptosis and the balance between pro- and antiangiogenic chemokine 
release. We would emphasize that these alterations probably are caused by direct effects of IFNγ 
effects on the AML cells because we used highly enriched leukemic cell populations in our studies.  
 IFN is supposed to induce the expression of MHC class II on the surfaces of various cell 
types and thereby probably converting them to nonprofessional APCs. The presentation of leukemia-
associated antigens to T cells may then be improved, but it has also been suggested that MHC II 
restricted antigen presentation by this excess of non-professional APCs may result in antigen-specific 
T cell anergy or induction of Treg cells (182). Also, a recently study concluded that IFN appeared to 
have a negative regulatory role of the in vivo DC function (185). Thus, further investigations have to 
clarify whether local IFNγ release will enhance or downregulate antileukemic T cell reactivity. 
The in vivo effects of IFN on malignant cells seem to differ and both suppression of 
tumorigenicity (182, 186) and enhancement of tumor growth or metastatic potential (182, 187) has 
been described. These differences can be caused by differences in the direct effects of IFNγ on the 
malignant cells, but indirect effects mediated via stromal cells may also be important. We 
characterized the direct effects of IFNγ on AML cells, but a recent experimental study in mice 
suggested that the crosstalk between leukemic and immunocompetent may be more important than 
the direct effects (188). In this model Stat-1, which is the major intracellular target for IFNγ receptor 
ligation in AML, is regarded as a tumor suppressor and considered as a key regulator of the 
surveillance of developing malignancies. In contrast to these previous studies, these authors 
described that Stat-1 acted as a tumor promoter for leukemia development, and absence of Stat-1 was 
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then associated with decreased MHC class I expression and thereby more efficient recognition of 
leukemia cells by NK cells. These experimental observations illustrate the importance of 
investigating potential antileukemic immune reactivity within the natural immunoregulatory network.  
 
Naive versus memory T cells  
Several studies (189-191) suggest that naive and memory T cells cannot be estimated by using only 
the typically CD45RA and CD45RO markers, respectively, and for an accurate estimation one has to 
use additional markers (i.e. CD62L, CD11a, CD27). However, de Rosa et al. report that when a third 
marker was included to identify naive cells, a population of cells were found to be  discordant. 
Functional studies and analysis of the Vβ repertoire suggest that the discordant cells appeared to be 
non-naive (190). Sallusto et al. (191) described that CCR7 identifies a subset of CD8+ memory cells 
that coexpress CD62L and de Rosa et al. (190) described that truly naive CD8+ cells had to be 
identified by three additional markers similar to CD4+ naive cells. Thus, the frequency of naive T 
cells among CD8+ and CD4+ CD45RA+ cells show a wide variation, and would be expected to vary 
even more in patients than for healthy individuals. From our study regarding the T cell expression of 
CD45RA and CD45RO in untreated AML patients (paper I), there can only be concluded that the 
AML patients are heterogeneous with regard to circulating CD45RA/RO cells, and this heterogeneity 
in membrane molecule expression probably reflects heterogeneity with regard to frequencies of 
memory and naive T cells. However, a proper examination of this question would be to combine 
CD4/CD8 with at least 3 additional markers to eliminate discordant cells, and then to investigate the 
Vβ repertoire of these cells. The CD45RA+ and CD45RO+ populations are heterogeneous in healthy 
individuals, and there is no reason to expect a less complex situation in patients. 
The possibly use of PEP005 in AML 
A recent study suggested that the active agent in the sap of Euphorbia peplus, ingenol 3-angelate 
(PEP005), had antileukemic activity that was mediated through the delta isoform of PKC (192). 
PEP005 induced apoptosis in AML cell lines as well as in primary AML cells, whereas normal 
hematopoietic progenitors were resistant to PEP005-induced apoptosis. However, the study included 
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primary AML cells only from a relatively small number of patients, and it will be important to 
investigate these effects in a larger group of well-characterized unselected patients. Preliminary 
studies of AML xenografts using the NB4 cell line in NOD/SCID/2m-/- mice show no prolonged 
survival for mice receiving PEP005. These animals die due to leukemic infiltrates in the brain but the 
tumor burden in abdominal lymph nodes and ovaries seem to be reduced (personal communication 
with Dr. E. Mc Cormack and Dr. KQ. Wang). A possible explanation for these observations could be 
that the antileukemic effect is not observed in the central nervous system due to the blood-brain 
barrier and thereby lower drug concentrations in this compartment.  
 The antileukemic action of PEP005 was proposed to be mediated through the activation of 
PKC- (192). PKC  is a family of 11 isoenzymes of which 8 show in vitro responsiveness to PEP005 
(classical , 1, II,  and novel , , 	, 
 PKCs) (193). PKC seem to have emerging and diverse roles 
in immune cell signaling (194), however the effect of PEP005 on T cell functions have not been 
examined previously. Our results suggest that PEP005 enhances the in vitro activation of T cells 
derived from patients with chemotherapy induced cytopenia (paper II), but an enhancement was 
observed only for a minority of patients when testing T cells derived from patients with untreated 
AML. This difference could be caused either by (i) the presence of IL2, this was added to the cultures 
only when testing cytopenic patients, or (ii) different culture conditions and especially the presence 
of peripheral blood components when testing cytopenic patients with the whole blood assay. The 
presence of AML cells probably does not have any major influence on the overall results because the 
effect of Pep005 was similar when we compared healthy controls and patients with untreated AML. 
However, differences in the AML cell phenotype, especially the constitutive release of 
immunoregulatory cytokines, may be important for certain patients and contribute to the variation 
between patients.  
Taken together these studies suggest that Pep005 should be tried in cancer therapy because 
(i) the drug seems to have direct antileukemic effects; (ii) the drug seems to enhance T cell reactivity 
and may therefore also enhance antileukemic immune reactivity. However, it remains to be clarified 
whether Pep005 will affect chemotaxis of immunocompetent cells and thereby their local recruitment 
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to the cancer cell compartments. These future studies have to include the effect of this drug on the 
AML cells release of T cell chemotactic chemokines. 
 
Disease-induced alterations in the cellular immune system in AML and multiple 
myeloma patients  
MM is a clonal B-cell malignancy characterised by an excess of mature plasma cells in the BM, and 
the large majority of patients has monoclonal immunoglobulin protein (complete molecules or only 
light chains) in serum and/or urine and usually develop decreased normal immunoglobulin (Ig) 
levels. The cellular immune system of patients with multiple myeloma has been examined 
previously, and several differences were then observed compared with our and others observation in 
AML patients: 
o a decreased CD4+/CD8+ ratio is usually observed in circulating T lymphocytes of patients with 
MM (95, 195), whereas in AML patients the CD4/CD8 ratio close to normal ((107) and paper I); 
o myeloma patients seem to have elevated TH1/TH2 ratio (88), whereas Panoskaltsis et al. (107) 
described TH1 and TH2 cytokine profiles close to normal in AML patients. 
In our comparison of myeloma and AML patients (paper II) we describe a difference in T cell 
cytokine release between these patients. Treatment-induced alterations probably contribute to this 
difference because our AML patients receive intensive chemotherapy alone, whereas the myeloma 
patients receive a different chemotherapy regimen in combination with autologous stem cell support.  
 
 
Autoantibodies in patients with malignant disorders 
It is well-established that autoimmunity can be associated with cancer, and one of the forms of its 
expression is the development of autoantibodies and eventually autoimmune disease (196). Several 
mutated or overexpressed proteins seem to be processed and presented to the immune system as 
tumor antigens leading to humoral or cellular responses (125). One of the most extensively studied 
cancer-associated antigens are p53 (197), but more recent studies have demonstrated that 
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autoantibodies agains a wide range of autoantigens can be detected in patients with malignant 
disorders (125, 198). Zhang et al. investigated a group of 174 cancer patients for autoantibodies 
against 7 known autoantigens, each autoantibody could then be detected in 10-20% of the patients 
but approximately half of the patients had at least one autoantobody (125). Thus, cancer-associated 
humoral autoimmunity is a common phenomenon, but autoimmune disease is uncommon (196). 
 Phage display is a technique in which bacteriophages are engineered to fuse a foreign peptide 
or protein with their capside proteins and hence expose or display it on their surface. The 
combination of phage display technology and immunoscreening can also be used to identify 
antibody-binding peptides (199, 200). Examination of peptide phage libraries allows the screening 
for autoantibodies without knowledge about the parental antigen (201), and it is then possible to 
profile specific immune responses in patient sera and identify new autoantigens. A recent study 
described the identification of peptides and cDNA encoded proteins that are recognized by breast 
cancer IgG antibodies but not by antibodies from healthy controls, and the reactivity of some of these 
antibodies seemed to be linked to survival (202). 
 The detection of autoantibodies may become important in future clinical medicine: 
o Detection of autoantibodies or autoimmune disease may be the first sign of cancer (196). 
o Analysis of autoantibodies may become useful in the screening for cancer and possibly cancer-
specific autoantibody profiles can be identified. 
o Although the clinical importance of autoantibody detection is uncertain, at least some studies 
suggest that detection of autoantibodies may have a prognostic impact. Detection of p53 
autoantibodies in breast cancer patients seem to be associated with high-grade tumors and poor 
survival (197), whereas a small clinical study suggested that antibodies against a specific peptide 
was associated with long survival  (202). 
o Antibody “fingerprints” to TAAs are proposed as a future biomarker for early cancer diagnosis 
and may thereafter function as guidance for individualized therapeutic interventions and to 
predict response to therapy or risk of relapse (203).  
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We examined AML patient sera for antibodies against cyclin B1 and the ribosomal p protein. We 
have described the novel findings of abnormal cytoplasmatic distribution related to constitutive 
expression of cyclin B1 in AML blasts, as well as the detection of a specific humoral immune 
response against cyclin B1 in sera from a minor subset of AML patients (paper V). In contrast, we 
did not detect autoantibodies against the SLE associated ribosomal P proteins in sera from untreated 
AML patients nor in sera from AML patients with chemotherapy-induced cell damage (paper IV). 
p53 antibodies in breast cancer seem to be associated with aggressive disease and poor survival. 
AML is one of the most aggressive malignancies with a median survival of only 3-4 months for 
patients only receiving supportive therapy. Even though other autoantibodies seem to be associated 
with aggressive disease, the frequency of AML patients with anti-cyclin B1 was similar to the 
frequency previously observed for less aggressive malignancies like prostate, gastric, breast, 
colorectal, lung, and hepatocellular cancers (198). This low frequency was observed even though a 
major part of AML patients show cytoplasmic cyclin B1 expression that has been associated with 
autoimmunity in other malignancies (204, 205). Furthermore, our analysis of AML patients receiving 
intensive chemotherapy suggest that neither the development of cyclin B1 nor ribosomal p protein 
antibodies is dependent of extensive tissue damage, at least not for immunocompromized AML 
patients receiving intensive chemotherapy. It seems more likely that at least the presence of anti-P 
antibodies are a part of a specific autoimmune disease process rather than a response to cell 
destruction, and this is also supported by proposals of SLE as a disease with an apoptotic clearance 
deficiency (206) and association of anti-P with organ-specific kidney (nephritis) disease in SLE 
(207). 
 
Concluding remarks 
The overall disease-free survival for patients with AML is less than 50% even for the younger 
patients who can receive the most intensive therapy, and there is obviously a need for a more 
effective therapy. Immunotherapy (e.g. targeting of autologous T cells) is considered as a possible 
therapeutic approach. Short time until lymphoid reconstitution after chemotherapy seems to be a 
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good prognostic factor in several malignancies, including AML. Both the cellular and humoral 
immune system in AML patients differ from healthy controls. The main aim of this thesis was 
therefore to characterize the immune system of patients with AML. Our results substantiate the 
hypothesis that even these immunocompromized patients have remaining immunocompetent cells 
that can be targeted by immunotherapy.  
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